Key facts for Q9967
- Billing unit
- 1 ML
- Locm 300-399mg/ml iodine,1ml
- ASP payment limit
- $0.186
- October 2026; +20.0% vs July 2026
- Practitioner MUE
- 300
- MAI 3
- OPPS status
- SI N
- NCCI exposure
- 5 col-2 pairs
- 100% allow a modifier
- Coverage articles
- 0
- none list this code
TL;DR
HCPCS Q9967 is the Level II code for Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml, billed per 1 ML. The Medicare Part B ASP payment limit for October 2026 is $0.186 per billing unit, up 20.0% from July 2026. The practitioner MUE allows up to 300 units per date of service (MAI 3), so a full 300-unit day is $55.80 at the current limit. Under OPPS it carries status indicator N. Diagnostic agents are usually packaged under OPPS (status N) in the hospital outpatient setting, so separate payment applies mainly in the physician office under Part B. The ASP crosswalk maps 95 NDCs to it, sold as Optiray 320, Ioversol Injection 678 MG/ML, Optiray 350 by Liebel-Flarsheim Company LLC, Bracco Diagnostics Inc., GE Healthcare Inc. It is the bundled column-2 code in 5 NCCI pairs, most often with Q9958, Q9960, Q9961. No current Billing and Coding Article lists Q9967, so coverage follows the FDA label, compendia and any applicable NCD.
Medicare Part B payment limit (ASP)
CMS sets the Part B payment limit for Q9967 at $0.186 per 1 ML for October 2026, derived from manufacturer average sales price plus 6%, compared with $0.155 in July 2026. Beneficiary coinsurance is 20%.
| Quarter | Payment limit | Per | Coinsurance |
|---|---|---|---|
| October 2026 | $0.186 | 1 ML | 20% |
| July 2026 | $0.155 | 1 ML | — |
NDC to HCPCS billing-unit conversion
The October 2026 ASP crosswalk maps 95 NDCs from 6 labelers to Q9967. Report the NDC in the claim's drug segment and bill the number of Q9967 units that equals the quantity administered divided by 1 ML; the last column gives units per full package.
| NDC | Drug name | Labeler | Package size | Billing units / package |
|---|---|---|---|---|
| 00019-1323-06 | Optiray 320 | Liebel-Flarsheim Company LLC | 50 × 25 | 1250 |
| 00019-1323-11 | Optiray 320 | Liebel-Flarsheim Company LLC | 100 × 12 | 1200 |
| 00019-1323-16 | Optiray 320 | Liebel-Flarsheim Company LLC | 150 × 12 | 1800 |
| 00019-1323-21 | Optiray 320 | Liebel-Flarsheim Company LLC | 200 × 12 | 2400 |
| 00019-1323-52 | Optiray 320 | Liebel-Flarsheim Company LLC | 50 × 20 | 1000 |
| 00019-1323-65 | Ioversol Injection 678 MG/ML | Liebel-Flarsheim Company LLC | 500 × 6 | 3000 |
| 00019-1323-78 | Optiray 320 | Liebel-Flarsheim Company LLC | 50 × 20 | 1000 |
| 00019-1323-87 | Optiray 320 | Liebel-Flarsheim Company LLC | 125 × 20 | 2500 |
| 00019-1323-90 | Optiray 320 | Liebel-Flarsheim Company LLC | 100 × 20 | 2000 |
| 00019-1323-95 | Optiray 320 | Liebel-Flarsheim Company LLC | 75 × 20 | 1500 |
| 00019-1333-06 | Optiray 350 | Liebel-Flarsheim Company LLC | 50 × 25 | 1250 |
| 00019-1333-11 | Optiray 350 | Liebel-Flarsheim Company LLC | 100 × 12 | 1200 |
| 00019-1333-16 | Optiray 350 | Liebel-Flarsheim Company LLC | 150 × 12 | 1800 |
| 00019-1333-21 | Optiray 350 | Liebel-Flarsheim Company LLC | 200 × 12 | 2400 |
| 00019-1333-65 | Ioversol Injection 741 MG/ML | Liebel-Flarsheim Company LLC | 500 × 6 | 3000 |
| 00019-1333-78 | Optiray 350 | Liebel-Flarsheim Company LLC | 50 × 20 | 1000 |
| 00019-1333-87 | Optiray 350 | Liebel-Flarsheim Company LLC | 125 × 20 | 2500 |
| 00019-1333-90 | Optiray 350 | Liebel-Flarsheim Company LLC | 100 × 20 | 2000 |
| 00019-1333-95 | Optiray 350 | Liebel-Flarsheim Company LLC | 75 × 20 | 1500 |
| 00270-1315-25 | Isovue-300 | Bracco Diagnostics Inc. | 30 × 10 | 300 |
| 00270-1315-35 | Isovue-300 | Bracco Diagnostics Inc. | 100 × 10 | 1000 |
| 00270-1315-45 | Isovue-300 | Bracco Diagnostics Inc. | 200 × 10 | 2000 |
| 00270-1315-95 | Isovue-300 | Bracco Diagnostics Inc. | 500 × 6 | 3000 |
| 00270-1316-35 | Isovue-370 | Bracco Diagnostics Inc. | 100 × 10 | 1000 |
| 00270-1316-45 | Isovue-370 | Bracco Diagnostics Inc. | 200 × 10 | 2000 |
| 00270-1316-95 | Isovue-370 | Bracco Diagnostics Inc. | 500 × 6 | 3000 |
| 00270-1412-15 | Isovue-M-300 | Bracco Diagnostics Inc. | 15 × 10 | 150 |
| 00270-7300-10 | Iomeron | Bracco Diagnostics Inc. | 100 × 56 | 5600 |
| 00270-7300-20 | Iomeron | Bracco Diagnostics Inc. | 200 × 10 | 2000 |
| 00407-1413-10 | Omnipaque 300 | GE Healthcare Inc. | 10 × 10 | 100 |
| 00407-1413-48 | Omnipaque 300 (Novaplus) | GE Healthcare Inc. | 500 × 10 | 5000 |
| 00407-1413-53 | Omnipaque 300 | GE Healthcare Inc. | 125 × 10 | 1250 |
| 00407-1413-59 | Omnipaque 300 | GE Healthcare Inc. | 30 × 10 | 300 |
| 00407-1413-61 | Omnipaque 300 | GE Healthcare Inc. | 50 × 10 | 500 |
| 00407-1413-62 | Omnipaque 300 | GE Healthcare Inc. | 75 × 10 | 750 |
| 00407-1413-63 | Omnipaque 300 | GE Healthcare Inc. | 100 × 10 | 1000 |
| 00407-1413-65 | Omnipaque 300 | GE Healthcare Inc. | 150 × 10 | 1500 |
| 00407-1413-66 | Omnipaque 300 | GE Healthcare Inc. | 200 × 10 | 2000 |
| 00407-1413-68 | Omnipaque 300 | GE Healthcare Inc. | 500 × 10 | 5000 |
| 00407-1413-69 | Omnipaque 300 | GE Healthcare Inc. | 125 × 10 | 1250 |
| 00407-1413-72 | Omnipaque 300 | GE Healthcare Inc. | 500 × 10 | 5000 |
| 00407-1413-86 | Omnipaque 300 | GE Healthcare Inc. | 50 × 10 | 500 |
| 00407-1413-87 | Omnipaque 300 | GE Healthcare Inc. | 100 × 10 | 1000 |
| 00407-1413-88 | Omnipaque 300 | GE Healthcare Inc. | 150 × 10 | 1500 |
| 00407-1413-89 | Omnipaque 300 | GE Healthcare Inc. | 500 × 10 | 5000 |
| 00407-1414-48 | Omnipaque 350 (Novaplus) | GE Healthcare Inc. | 500 × 10 | 5000 |
| 00407-1414-72 | Omnipaque 350 | GE Healthcare Inc. | 500 × 10 | 5000 |
| 00407-1414-76 | Omnipaque 350 | GE Healthcare Inc. | 125 × 10 | 1250 |
| 00407-1414-82 | Omnipaque 350 | GE Healthcare Inc. | 50 × 10 | 500 |
| 00407-1414-84 | Omnipaque 350 | GE Healthcare Inc. | 100 × 10 | 1000 |
| 00407-1414-85 | Omnipaque 350 | GE Healthcare Inc. | 125 × 10 | 1250 |
| 00407-1414-86 | Omnipaque 350 | GE Healthcare Inc. | 150 × 10 | 1500 |
| 00407-1414-87 | Omnipaque 350 | GE Healthcare Inc. | 200 × 10 | 2000 |
| 00407-1414-88 | Omnipaque 350 | GE Healthcare Inc. | 500 × 10 | 5000 |
| 00407-1414-89 | Omnipaque 350 | GE Healthcare Inc. | 50 × 10 | 500 |
| 00407-1414-90 | Omnipaque 350 | GE Healthcare Inc. | 75 × 10 | 750 |
| 00407-1414-91 | Omnipaque 350 | GE Healthcare Inc. | 100 × 10 | 1000 |
| 00407-1414-93 | Omnipaque 350 | GE Healthcare Inc. | 150 × 10 | 1500 |
| 00407-1414-94 | Omnipaque 350 | GE Healthcare Inc. | 200 × 10 | 2000 |
| 00407-1414-95 | Omnipaque 350 | GE Healthcare Inc. | 125 × 10 | 1250 |
Medically Unlikely Edits (MUE)
CMS publishes 2 MUE values for Q9967. For practitioners the limit is 300 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.
| Setting | MUE (units/DOS) | MAI | CMS rationale |
|---|---|---|---|
| Practitioner services | 300 | 3 Date of Service Edit: Clinical | Prescribing Information |
| Facility outpatient hospital | 300 | 3 Date of Service Edit: Clinical | Prescribing Information |
MUE for Q9967 in every setting opens the lookup with this code filled in, next to any other code on the same claim.
NCCI edits and add-on relationships
In the practitioner PTP file v323r0 (effective October 1, 2026), Q9967 is the column-2 code in 5 active pairs, 100% of which allow a modifier (indicator 1), and the column-1 code in 5. 0 historical pairs have been deleted over time. CMS's most frequent rationale: Mutually exclusive procedures.
When billed with these column-1 codes, Q9967 is the bundled component unless the pair allows a modifier and the documentation supports a distinct service.
These codes are considered components of Q9967 when reported together on the same date of service.
The counts above are exposure, not answers for a specific claim. Check Q9967 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.
Q9967 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.
Medicare coverage articles
No current Billing and Coding Article lists Q9967 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.
Hospital outpatient (OPPS) status
In the October 2026 OPPS Addendum B, Q9967 carries status indicator N. Status N means payment is packaged into the associated procedure and no separate OPPS payment is made.
Ambulatory surgical center (ASC) payment
In the October 2026 ASC Addendum BB (covered ancillary services), Q9967 carries payment indicator N1, which CMS defines as "Packaged service/item; no separate payment made". An N1 drug is packaged in the ASC: the facility receives no separate payment because the surgical procedure's rate already includes it.
Common denials for Q9967 and how to prevent them
For teams evaluating QuickIntell software
Evaluate a coding workflow for Q9967
Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
In QuickIntell research
- October 2026 ASP movers report: Q9967's payment limit moved +20.0% against July 2026, one of 75 drug codes that moved 20% or more.
- 2026 Q4 most-bundled codes report: Q9967 is the column-2 code in 5 active practitioner NCCI pairs, one of 12 Part B drug codes that NCCI bundles at all.
- J codes by drug name: Every code for the same drug, generic or brand, in one A-Z index.
Frequently asked questions — HCPCS Q9967
What does HCPCS code Q9967 describe?
Q9967 is defined by CMS as "Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml". Each billing unit represents 1 ML, so the units reported on the claim must equal the dose administered divided by that unit.
Is Q9967 a CPT code?
No. Q9967 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as low osmolar contrast material; CPT codes are five-character codes maintained by the AMA. On a Part B claim Q9967 reports the drug itself in 1 ml units, and the administration is billed on its own line.
What is the Medicare reimbursement for Q9967 in October 2026?
The ASP-based payment limit is $0.186 per 1 ML, with 20% beneficiary coinsurance. The July 2026 limit was $0.155. Commercial payers use their own fee schedules.
How many units of Q9967 can be billed per day?
The practitioner Medically Unlikely Edit is 300 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.
Which NDCs map to Q9967?
The October 2026 ASP crosswalk lists 95 NDCs from 6 labelers: Optiray 320 (Liebel-Flarsheim Company LLC); Ioversol Injection 678 MG/ML (Liebel-Flarsheim Company LLC); Optiray 350 (Liebel-Flarsheim Company LLC); Ioversol Injection 741 MG/ML (Liebel-Flarsheim Company LLC). For example NDC 00019-1323-06 (package size 50) equals 1,250 billing units of Q9967.
Does Q9967 have NCCI bundling edits?
In the v323r0 practitioner PTP file, Q9967 appears as the column-2 (bundled) code in 5 active pairs and as the column-1 code in 5. 100% of the column-2 pairs allow a modifier (indicator 1). The most frequent column-1 partners are Q9958, Q9960, Q9961, Q9962, Q9963, and CMS's leading rationale is "Mutually exclusive procedures".
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- HCPCS Level II alpha-numeric file, October 2026Version October 2026 · effective 2026-10-01 · file HCPC2026_OCT_ANWEB_09232026.txtSHA-256 c25240c63108756d…
- Medicare Part B Drug Payment Limit File, October 2026Version October 2026 · effective 2026-10-01 · file section 508 version of October 2026 Medicare Part B Payment Limit File 091626.csvSHA-256 508fba376a29e099…
- Medicare Part B Drug Payment Limit File, July 2026Version July 2026 · effective 2026-07-01 · file section 508 version of July 2026 Medicare Part B Payment Limit File updated 082026.csvSHA-256 13bb5b644b92b574…
- ASP NDC-HCPCS Crosswalk, October 2026Version October 2026 · effective 2026-10-01 · file section 508 version of October 2026 ASP NDC-HCPCS Crosswalk 091126.csvSHA-256 5cb78f0c2ee786ba…
- NCCI MUE table, practitioner services, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file MCR_MUE_PractitionerServices_Eff_10-01-2026.csvSHA-256 ef038efaf902b7bd…
- NCCI MUE table, facility services, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file MCR_MUE_OutpatientHospitalServices_Eff_10-01-2026.csvSHA-256 3af9f4e99cc587e2…
- NCCI MUE table, dme services, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file MCR_MUE_DMESupplierServices_Eff_10-01-2026.csvSHA-256 6fa4fbba852f7b74…
- NCCI PTP edits, practitioner, v323r0 (four files)Version v323r0 (2026 Q4) · effective 2026-10-01 · file ccipra-v323r0-f1.TXTSHA-256 7793c0b6686c1e22…
- NCCI Add-On Code edits, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file AOC_V2026Q4-F-MCR.xlsxSHA-256 eabb519623134549…
- OPPS Addendum B, October 2026Version October 2026 · effective 2026-10-01 · file 508-compliant-version-2026_October_Web_Addendum_B.09.28.26.csvSHA-256 6ad7393a318bf1b9…
- ASC Addendum BB (covered ancillary services), October 2026Version October 2026 · effective 2026-10-01 · file Oct 2026 ASC BB.txtSHA-256 63cdd7c72aba7a25…
- Medicare Coverage Database, current Billing and Coding Articles exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file article.csvSHA-256 b475751458564786…
Disclaimer
This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.